AI Insights · Timothy · October 2024
Top 5 Medical Apps in New Zealand Q3 2024 Performance
Explore the trends in downloads, revenue, and active users for the top medical apps in New Zealand during Q3 2024, with data insights from Sensor Tower.
In the third quarter of 2024, the medical app sector in New Zealand showed varied performance across the top five apps, with distinct trends in downloads, revenue, and active user engagement. This analysis, based on data from Sensor Tower, provides a snapshot of the market dynamics during this period.
Huckleberry: Baby & Child, developed by Huckleberry Labs Inc., experienced fluctuating weekly revenue, peaking at approximately $1.9K in mid-August and again in late September. Downloads remained relatively stable, ranging from 211 to 380 weekly, while active users saw a slight increase towards the end of the quarter, reaching around 8.9K.
SnoreLab: Record Your Snoring, by Reviva Softworks Ltd, maintained a moderate revenue stream, with weekly figures varying between $397 and $644. Despite a gradual decline in downloads, weekly active users hovered around 800 to 900, indicating consistent user engagement.
The Monash FODMAP Diet app from Monash University recorded a steady revenue flow, averaging around $300 to $400 weekly. Downloads remained low, with numbers fluctuating between 24 and 47 weekly, while active users showed stability within the 500 to 600 range.
Smart Sleep Coach by Pampers™ saw a notable increase in active users, growing from 301 to 753 throughout the quarter. Revenue peaked at $344 in the last week of September, while downloads showed a downward trend, starting at 649 and decreasing to 139 by the quarter's end.
Finally, the Sanford Guide, although lacking substantial download numbers, managed to sustain its revenue, with weekly figures ranging from $65 to $190.
These insights, derived from Sensor Tower data, illustrate the diverse performance patterns of medical apps in New Zealand during Q3 2024. For more comprehensive insights and analysis, visit Sensor Tower.